Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 7,724 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Withdrawn Phase 1 Interventional

PDT Plus Vitamin D3 for Anal Dysplasia

NCT02698293
View directory record Official record
Conditions
Anal Dysplasia, Carcinoma in Situ
Interventions
Gliolan, Vitamin D3 cholecalciferol), Photodynamic Therpay
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

NCT03200587
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Avelumab, Cabozantinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00003721
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
incyclinide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Oct 28, 2026, 10:52 AM EDT
Not listed Phase 2 Interventional

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

NCT05223816
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions
VG161, Nivolumab Injection [Opdivo]
Drug
Lead sponsor
Virogin Biotech Canada Ltd
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

NCT04249284
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, BMS-986165 prototype 1, BMS-986165 prototype 2
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Healthy Futures Project: A Community Based Obesity Prevention Program

NCT00685555
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Switch active lifestyles brought to you by MediaWise, Switch active lifestyles from MediaWise
Behavioral
Lead sponsor
National Institute on Media and the Family
Other
Eligibility
8 Years to 13 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 28, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

NCT07390955
View directory record Official record
Conditions
HIV
Interventions
ePGT121v1-LS (IV), PGDM1400LS (IV), VRC07-523LS (IV), ePGT121v1-LS (SC), PGDM1400LS (SC), VRC07-523LS (SC)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Terminated Phase 1 Interventional

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

NCT02630043
View directory record Official record
Conditions
Neuroblastoma
Interventions
Tolcapone, Oxaliplatin
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
0 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 28, 2026, 10:52 AM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 28, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SAFEGUARD Level Up Study

NCT07286955
View directory record Official record
Conditions
Risk Reduction Behavior, Suicide Prevention, Risky Behavior, Mental Health, Resilience, Performance at Work
Interventions
Level Up
Behavioral
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00841555
View directory record Official record
Conditions
Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions
temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Light Therapy to Improve Blood Circulation in People With Chronic Heel Pain

NCT01882725
View directory record Official record
Conditions
Defective; Circulation
Interventions
Erchonia HP Scanner (HPS)
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

NCT01138917
View directory record Official record
Conditions
Burns
Interventions
ReCell and Split-thickness skin graft
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 28, 2026, 10:52 AM EDT
Terminated Phase 1 Interventional

A Study of ASP1012 in Adults With Solid Tumors

NCT06171178
View directory record Official record
Conditions
Solid Tumor
Interventions
ASP1012, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Auditory-Perceptual Training Via Telepractice

NCT04858035
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Perceptual training, Production training
Behavioral
Lead sponsor
Montclair State University
Other
Eligibility
9 Years to 15 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Upper Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Healthy Futures Evaluation

NCT02554825
View directory record Official record
Conditions
Sexual Behavior
Interventions
Healthy Futures, Control
Behavioral
Lead sponsor
JSI Research & Training Institute, Inc.
Other
Eligibility
10 Years to 15 Years
Enrollment
1,344 participants
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 28, 2026, 10:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

NCT06480240
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
OBI-992
Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Glendale, California • La Jolla, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 28, 2026, 10:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)

NCT07226440
View directory record Official record
Conditions
Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

NCT01162889
View directory record Official record
Conditions
Healthy
Interventions
Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 28, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204
View directory record Official record
Conditions
Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Interventions
ASP5834, panitumumab
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens

NCT00177333
View directory record Official record
Conditions
Abortion, Induced, Vomiting
Interventions
Doxycycline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 28, 2026, 10:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Results available

HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors

NCT02232243
View directory record Official record
Conditions
Solid Tumor
Interventions
Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
Drug
Lead sponsor
Peng Wang, MD PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 28, 2026, 10:52 AM EDT